Orchard Therapeutics Limited is hoping to gain the first approval by the end of the year for its one-time gene therapy for metachromatic leukodystrophy (MLD), Libmeldy (OTL-2000), in the EU. A launch is expected to follow in early 2021.
Libmeldy (cryopreserved autologous CD34+ cells encoding the arylsulfatase-A, or ARSA, gene) has been granted a positive opinion by the European...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
